Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer

Inclusion Criteria: 1. Histologically confirmed metastatic pancreatic adenocarcinoma 2. Patients aged between 18 and 75 3. ROBO1 expression in malignancy tissues detected by immuno-histochemistry (IHC) 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 5. Life expectancy greater than 3 months 6. Subjects must have measurable disease as defined by RECIST 1.1 criteria 7. Satisfactory organ and bone marrow function: White blood cell count (WBC) ≥ 3.0×10\^9/L, Platelets ≥ 70×10\^9/L, Hb ≥ 9.0g/dL, lymphocyte (LY) ≥ 0.7×10\^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and amylase \< 1.5 × upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration 8. Karnofsky score ≥ 60 9. Ability to give informed consent Exclusion Criteria: 1. Previously treated with any gene therapy products 2. Patients who are receiving any other investigational agents 3. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant 4. Active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnesses 5. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease) 6. Concurrent opportunistic infections